Skip to content

Biogen Reverses Course, Asks FDA To Approve Failed Alzheimer’s Drug

October 24, 2019

Biogen, a United States drug manufacturer, has asked the Food and Drug Administration (FDA), to approve their Alzheimer’s drug, Aducanumab. Their request is highly unusual, as it’s the same drug they suspended testing just seven months ago because it was ineffective in Phase-2 clinical trials.   The Biogen announcement, shocked the scientific community and the…

Read More
Scroll To Top